Find clinical trials for Non-Small-Cell Lung Cancer in Durham, NC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Small-Cell Lung Cancer trials near Durham, NC, USA:
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...
Phase 2
Chapel Hill, North Carolina, United States and 71 other locations
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...
Phase 2, Phase 3
Greensboro, North Carolina, United States and 61 other locations
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...
Phase 3
Durham, North Carolina, United States and 230 other locations
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combina...
Phase 3
Greensboro, North Carolina, United States and 201 other locations
study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) wit...
Phase 1, Phase 2
Chapel Hill, North Carolina, United States and 28 other locations
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alter...
Phase 1, Phase 2
Durham, North Carolina, United States and 39 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small...
Phase 1, Phase 2
Chapel Hill, North Carolina, United States of America and 7 other locations
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (...
Phase 3
Durham, North Carolina, United States and 196 other locations
and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to...
Phase 3
Cary, North Carolina, United States and 98 other locations
PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will ev ...
Phase 2
Durham, North Carolina, United States and 1 other location
Clinical trials
Research sites
Resources
Legal